Wilkins Miller Wealth Management LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Wilkins Miller Wealth Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,008 shares of the company's stock, valued at approximately $291,000.

A number of other institutional investors have also recently bought and sold shares of JNJ. Hall Capital Management Co. Inc. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $3,948,000. Liberty Square Wealth Partners LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $296,000. Cypress Asset Management Inc. TX acquired a new position in Johnson & Johnson during the fourth quarter worth $5,330,000. Ameriflex Group Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $550,000. Finally, United Advisor Group LLC boosted its stake in shares of Johnson & Johnson by 17.7% in the 4th quarter. United Advisor Group LLC now owns 6,547 shares of the company's stock valued at $947,000 after purchasing an additional 984 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.2%

Shares of NYSE:JNJ traded up $0.31 during midday trading on Tuesday, reaching $153.25. The company had a trading volume of 6,979,932 shares, compared to its average volume of 7,961,247. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock has a market cap of $368.73 billion, a PE ratio of 23.05, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business's 50 day moving average price is $155.05 and its 200 day moving average price is $153.65.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.39%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.